for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QGEN.N

Latest Trade

50.59USD

Change

0.67(+1.34%)

Volume

404,300

Today's Range

49.86

 - 

50.59

52 Week Range

25.06

 - 

52.79

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
49.92
Open
50.46
Volume
404,300
3M AVG Volume
32.03
Today's High
50.59
Today's Low
49.86
52 Week High
52.79
52 Week Low
25.06
Shares Out (MIL)
228.49
Market Cap (MIL)
11,523.00
Forward P/E
24.80
Dividend (Yield %)
--

Next Event

Qiagen NV at Berenberg and Goldman Sachs German Corporate Conference (Virtual)

Latest Developments

More

Qiagen Acquires Remaining Stake In Neumodx Molecular For $248 Mln

Bio-Techne And Qiagen Announce Expansion And Extension Of Exosome Partnership

Qiagen To Launch Digital Test In U.S. For SARS-CoV-2 Antibodies Detection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry

Biotechnology & Drugs

Contact Info

Hulsterweg 82

5912 PL

Netherlands

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Lawrence A. Rosen

Independent Chairman of the Supervisory Board

Thierry Bernard

Chief Executive Officer, Senior Vice President - Molecular Diagnostics Business Area, Member of the Executive Committee

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Stephane Bancel

Independent Member of the Supervisory Board

Metin Colpan

Independent Member of the Supervisory Board

Key Stats

2.64 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.4K

2018

1.5K

2019

1.5K

2020(E)

1.8K
EPS (USD)

2017

1.270

2018

1.340

2019

1.430

2020(E)

2.020
Price To Earnings (TTM)
1,155.02
Price To Sales (TTM)
7.15
Price To Book (MRQ)
4.35
Price To Cash Flow (TTM)
52.20
Total Debt To Equity (MRQ)
65.09
LT Debt To Equity (MRQ)
53.42
Return on Investment (TTM)
0.32
Return on Equity (TTM)
0.26

Latest News

Latest News

U.S. plans for hundreds of millions of cheap, fast COVID-19 tests

U.S. manufacturers are sharply increasing production of cheap, fast - but less accurate - COVID-19 tests, aiming for 100 million per month by year end that will enable schools and workplaces to significantly expand testing.

Qiagen readies launch of rapid COVID-19 antigen test

German diagnostic test maker Qiagen on Tuesday said it planned to launch a COVID-19 antigen test that can provide results in 15 minutes and test about 30 samples in an hour.

Qiagen chairman quits after Thermo Fisher's takeover bid fails

Qiagen <QIA.DE> said its non-executive Chairman Hakan Bjoerklund had resigned with immediate effect after the genetic testing company's shareholders rejected an improved takeover offer from Thermo Fisher <TMO.N>.

Thermo Fisher's Qiagen bid fails after target gets COVID testing boost

Thermo Fisher <TMO.N> has walked away from its takeover deal with Qiagen <QIA.DE> after the German genetic testing specialist's earnings were boosted by coronavirus diagnostics, leaving its shareholders reluctant to cash out.

Thermo Fisher ends deal agreement for genetic testing firm Qiagen

Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met. Thermo Fisher's revised offer had valued Qiagen at 11.3 billion euros ($13.38...

Thermo Fisher to update on Qiagen tender offer on Thursday

Thermo Fisher Scientific <TMO.N> said that the results of its sweetened takeover offer for German genetic testing company Qiagen <QIA.DE> would be unveiled on Thursday or soon thereafter.

Davidson Kempner says again it will not be tendering Qiagen shares

Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen <QIA.DE>, days after Thermo Fisher Scientific <TMO.N> said its offer to buy the German genetic test maker expires soon.

Davidson Kempner says again it will not be tendering Qiagen shares

Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen , days after Thermo Fisher Scientific said its offer to buy the German genetic test maker expires soon.

Qiagen investor Davidson Kempner ups stake to 8%

Hedge fund Davidson Kempner said on Monday it had raised its stake in takeover target Qiagen <QIA.DE> to 8% from 7.3% previously, reaffirming its opposition to Thermo Fisher's <TMO.N> 11.3 billion euro ($13.3 billion) bid.

Davidson Kempner ups stake in Qiagen to 7.3%

Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen <QIA.DE> to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Qiagen investor PSquared won't tender shares in Thermo Fisher bid

Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen <QIA.DE>, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.

Breakingviews - Corona Capital: Newspapers, 747s

Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

PRESS DIGEST-Financial Times - July 17

The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Thermo Fisher's sweetened Qiagen bid fails to win over key investor

Thermo Fisher Scientific <TMO.N> raised its bid for Qiagen <QIA.DE> by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.

Davidson Kempner spurns Thermo Fisher's Qiagen offer as 'wholly inadequate'

Hedge fund Davidson Kempner said on Wednesday Thermo Fisher Scientific's <TMO.N> offer to buy German genetic test maker Qiagen <QIA.DE> was "wholly inadequate" and that it would not be tendering its shares into the deal at the current price.

Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's <TMO.N> current offer to acquire German genetic test maker Qiagen NV <QIA.DE> to be "inadequate" and would not tender its shares into the offer.

UPDATE 1-Qiagen shareholder Davidson Kempner says Thermo Fisher offer 'inadequate'

Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's current offer to acquire German genetic test maker Qiagen NV to be "inadequate" and would not tender its shares into the offer.

MORNING BID-One step forward, two steps back

A look at the day ahead from Dhara Ranasinghe, senior markets correspondent, EMEA. The views expressed are her own.

European shares enter fourth day of declines, energy firms drag

European shares extended losses for a fourth straight session on Friday on worries that an economic recovery may fizzle out as coronavirus cases continue to rise globally.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up